SEC Form 4 · accession 0001055726-19-000008
INOVIO PHARMACEUTICALS, INC. · INO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David B. Weiner
Director
Period of report
Mar 5, 2019
Accepted (ET)
Mar 7, 2019 · 5:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001055726
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 5, 2019 | M | 11,667 | — | A | 778,292 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1 | — | Mar 5, 2019 | M | 11,667 | D | — | — | Common Stock | 11,667 | 23,333 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 5, 2019; 11,667 shares will vest on March 5, 2020; 11,666 shares will vest on March 5, 2021. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.